

GRIFOLS

Grifols looks into acquiring Diesse, an Italian company specialized in *in vitro* diagnostics

The completion of this transaction depends of the result of the due diligence process, which will last approximately two months

Barcelona, April 18, 2007. Grifols, a holding company in the pharmaceutical-hospital sector, has signed an agreement to acquire the Italian diagnostics company Diesse (Diagnostica Senese S.p.A.). The definitive close of this transaction depends on the results of the due diligence process, which is estimated to last through June.

The acquisition of Diesse will strengthen Grifols' Diagnostic Division, growing and diversifying the company's portfolio of products to cover other specializations in which the Italian company has years of experience and has gained international prestige. It will also contribute to accelerating the expansion of this division in line with the company's global strategy.

Currently, Grifols and Diesse maintain various collaborative agreements through which the Grifols distributes Diesse products such as the Chorus system in Spain, Portugal, Chile, UK and the United States. These products complement the line of immunology products by Grifols' Diagnostic division which includes the Triturus autoanalyzer and a range of reagents and other products. This commercial relationship has offered each company insight into the other and has awoken interest on the part of Grifols in integrating the other business into its structure.

About Diesse

Diesse is a company which is located in Sienna and has a staff of 140 employees, facilities of about 8,000m², and generated a turnover of 16 million euros in 2006. Its experienced R&D team develops and manufactures products and systems for clinical diagnostics. Since 1982, it has directed its efforts in the fields of haematology, infectious serology and microbiology developing products of an excellent quality which have allowed the company to expand into strategic markets. Their activities in developing single test products for rapid immunology tests are aimed at laboratories in private medical clinics known as Points of Care. This line

of business which is just taking off and has attractive margins and a high potential for growth.

About Grifols

Grifols is a holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Grifols turnover for 2006 rose to 649 million euros, of which the Diagnostic division accounted for 11.5%. Grifols has been operating in Italy since 1997 and its Italian affiliate has closed out the fiscal year 2006 with sales of 57 million euros, ranking it as the third country in volume of sales after the USA and Spain, respectively.

Since May 2006, the company has been listed on the Spanish Stock Market and forms part of the IBEX Medium Cap index. Currently it is the first company in Europe in the plasma derivatives sector and the fourth in production in the world. In the following years, the company will strengthen its leadership in the industry as a vertically integrated company thanks to its existing investments which have ensured the company's supply of its primary material, plasma, from 72 plasmapheresis centers in the United States. In terms of fractionation capacity, the manufacturing facilities in Barcelona (Spain) and Los Angeles (USA) will allow the company to respond to growing market demands.